Utilising this theory could help manage the often-fatal problem of malignant cells becoming resistant to chemotherapy.

The patient recovered well and was discharged 10 days later, with her weight dropping from 116 kg to 96 kg post-surgery.

The ovarian cancer market has transformed in recent years, driven by the expanding use of PARP inhibitors, antiangiogenic ...

Loose Women star Kaye Adams has been left stunned by her friend Karen MacKenzie's reaction to being diagnosed with breast ...

Experts worry about the uptick in cases as more Gen Xers and millennials are being diagnosed with a variety of ...

The FDA grants fast track designation to PHST001, an antibody targeting CD24, for advanced platinum-resistant and ...

Context Therapeutics offers a compelling long opportunity, with three differentiated bispecific T-cell engagers. Click here ...

Anixa Biosciences, Inc. ("Anixa" or the "Company") (NASDAQ: ANIX), a biotechnology company focused on the treatment and prevention of cancer, today announced that its CEO, Dr. Amit Kumar, was ...

The median progression-free survival was 6.54 months in the relacorilant arm and 5.52 months in the control arm. The combination of relacorilant and nab-paclitaxel can improve survival outcomes ...

Introduction: Ovarian cancer (OC) exhibits high mortality and chemoresistance rates ... aucMaxRank set to 5% to determine the top-ranking genes contributing to each pathway activity score. 2.4 ...

Around one in 10 women will develop ovarian cysts at some point during their lives, and while the prospect of a cyst growing on your ovaries could set off alarm bells, they aren’t something you ...